Published in Dig Dis Sci on April 27, 2011
American Gastroenterological Association technical review on constipation. Gastroenterology (2013) 3.27
Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments. World J Gastroenterol (2014) 0.89
Drug development for the irritable bowel syndrome: current challenges and future perspectives. Front Pharmacol (2013) 0.88
Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies. World J Gastroenterol (2014) 0.86
Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors. BMC Pharmacol (2012) 0.83
Effects of lubiprostone on pacemaker activity of interstitial cells of cajal from the mouse colon. Korean J Physiol Pharmacol (2014) 0.79
Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol (2014) 0.78
Chemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging Treatments. Front Pharmacol (2016) 0.78
Comprehensive self-management reduces the negative impact of irritable bowel syndrome symptoms on sexual functioning. Dig Dis Sci (2012) 0.77
Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits? Naunyn Schmiedebergs Arch Pharmacol (2011) 0.77
A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa. Pharmacol Res Perspect (2015) 0.76
Lubiprostone vs Senna in postoperative orthopedic surgery patients with opioid-induced constipation: a double-blind, active-comparator trial. World J Gastroenterol (2014) 0.75
Resting anal pressure, not outlet obstruction or transit, predicts healthcare utilization in chronic constipation: a retrospective cohort analysis. Neurogastroenterol Motil (2015) 0.75
ClC-2 regulation of intestinal barrier function: Translation of basic science to therapeutic target. Tissue Barriers (2015) 0.75
Functional bowel disorders. Gastroenterology (2006) 20.72
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci (1993) 7.98
The burden of selected digestive diseases in the United States. Gastroenterology (2002) 6.79
CLC chloride channels and transporters: from genes to protein structure, pathology and physiology. Crit Rev Biochem Mol Biol (2008) 5.03
Chronic constipation. N Engl J Med (2003) 4.58
Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology (1991) 3.90
Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci (1998) 3.74
The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol (2002) 3.59
Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol (2005) 3.10
Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther (2007) 2.79
Onset and disappearance of gastrointestinal symptoms and functional gastrointestinal disorders. Am J Epidemiol (1992) 2.54
SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents. Am J Physiol Cell Physiol (2004) 2.33
An epidemiological survey of constipation in canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol (2001) 2.30
Epidemiology of constipation (EPOC) study in the United States: relation of clinical subtypes to sociodemographic features. Am J Gastroenterol (1999) 2.30
A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am J Gastroenterol (2000) 2.27
The health-related quality of life and economic burden of constipation. Pharmacoeconomics (2005) 2.14
A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci (1989) 2.08
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther (2008) 2.06
Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol (2006) 1.94
Systematic review on the management of chronic constipation in North America. Am J Gastroenterol (2005) 1.85
Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology (2004) 1.68
Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterol (2002) 1.63
Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology (2009) 1.59
Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol (2004) 1.58
Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther (2008) 1.50
The treatment of chronic constipation in adults. A systematic review. J Gen Intern Med (1997) 1.49
Distribution of ClC-2 chloride channel in rat and human epithelial tissues. Am J Physiol Cell Physiol (2002) 1.44
A synthetic prostone activates apical chloride channels in A6 epithelial cells. Am J Physiol Gastrointest Liver Physiol (2008) 1.35
Intestinal permeability and irritable bowel syndrome. Neurogastroenterol Motil (2007) 1.33
Review article: the therapy of constipation. Aliment Pharmacol Ther (2001) 1.30
Adverse effects of laxatives. Dis Colon Rectum (2001) 1.28
Costs of care for irritable bowel syndrome patients in a health maintenance organization. Am J Gastroenterol (2001) 1.27
Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci (2009) 1.19
Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol (2007) 1.17
Dyssynergic defecation. Gastroenterol Clin North Am (2001) 1.13
Epidemiology of irritable bowel syndrome in Chinese. Dig Dis Sci (2002) 1.12
The treatment of chronic constipation in elderly people: an update. Drugs Aging (2004) 1.11
Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol (2008) 1.09
Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse. J Pharmacol Exp Ther (2010) 1.08
Enteric nervous system: sensory physiology, diarrhea and constipation. Curr Opin Gastroenterol (2010) 1.06
Effects of lubiprostone on human uterine smooth muscle cells. Prostaglandins Other Lipid Mediat (2008) 1.05
Lubiprostone stimulates duodenal bicarbonate secretion in rats. Dig Dis Sci (2009) 1.03
ClC-2 chloride secretion mediates prostaglandin-induced recovery of barrier function in ischemia-injured porcine ileum. Gastroenterology (2004) 1.03
Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci (2002) 1.02
Lubiprostone stimulates secretion from tracheal submucosal glands of sheep, pigs, and humans. Am J Physiol Lung Cell Mol Physiol (2009) 1.02
Lubiprostone reverses the inhibitory action of morphine on mucosal secretion in human small intestine. Dig Dis Sci (2010) 1.00
Increasing oral fluids in chronic constipation in children. Gastroenterol Nurs (1999) 0.97
Is constipation associated with decreased physical activity in normally active subjects? Am J Gastroenterol (2005) 0.96
Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review. Qual Life Res (2000) 0.94
Lubiprostone ameliorates the cystic fibrosis mouse intestinal phenotype. BMC Gastroenterol (2010) 0.93
Use of the chloride channel activator lubiprostone for constipation in adults with cystic fibrosis: a case series. Ann Pharmacother (2010) 0.90
Effect of oral dioctyl sodium sulfosuccinate on intake-output studies of human small and large intestine. Gastroenterology (1985) 0.85
Lubiprostone: evaluation of the newest medication for the treatment of adult women with constipation-predominant irritable bowel syndrome. Int J Womens Health (2010) 0.85
The laxative effects of lactulose in normal and constipated subjects. J Clin Gastroenterol (1981) 0.83
Prostaglandin E2-induced colonic secretion in patients with and without colorectal neoplasia. BMC Gastroenterol (2010) 0.80
Treatment of constipation in geriatric and chronically ill patients: a comparison. South Med J (1978) 0.80
Lubiprostone: clinical applications beyond constipation. World J Gastroenterol (2009) 0.76
Efficacy and safety of traditional medical therapies for chronic constipation: systematic review. Am J Gastroenterol (2005) 3.10
Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol (2009) 1.96
Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol (2009) 1.54
Treatment of postoperative ileus after bowel surgery with low-dose intravenous erythromycin. Urology (2007) 1.52
Digital rectal examination is a useful tool for identifying patients with dyssynergia. Clin Gastroenterol Hepatol (2010) 1.43
Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study. Indian J Gastroenterol (2009) 1.39
Fructose intolerance: an under-recognized problem. Am J Gastroenterol (2003) 1.22
Fructose intolerance in IBS and utility of fructose-restricted diet. J Clin Gastroenterol (2008) 1.16
Investigation of anal motor characteristics of the sensorimotor response (SMR) using 3-D anorectal pressure topography. Am J Physiol Gastrointest Liver Physiol (2010) 1.05
Constipation in pregnancy: prevalence, symptoms, and risk factors. Obstet Gynecol (2007) 1.03
Neurotrophin-3 improves functional constipation. Am J Gastroenterol (2003) 1.02
Functional chest pain: nociception and visceral hyperalgesia. J Clin Gastroenterol (2005) 1.02
A controlled trial of an intervention to improve urinary and fecal incontinence and constipation. J Am Geriatr Soc (2010) 0.99
Cholestyramine--a useful adjunct for the treatment of patients with fecal incontinence. Int J Colorectal Dis (2007) 0.99
Medical and surgical management of pelvic floor disorders affecting defecation. Am J Gastroenterol (2012) 0.99
Functional chest pain: esophageal or overlapping functional disorder. J Clin Gastroenterol (2007) 0.99
Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. Curr Gastroenterol Rep (2014) 0.94
Rectoanal sensorimotor response in humans during rectal distension. Dis Colon Rectum (2007) 0.92
Anorectal dysfunction after surgical treatment for cervical cancer. J Am Coll Surg (2002) 0.92
Pharmacologic management of chronic constipation. Gastroenterol Clin North Am (2010) 0.89
Anorectal physiology and pathophysiology in the elderly. Clin Geriatr Med (2014) 0.88
Neurophysiological testing in anorectal disorders. Expert Rev Gastroenterol Hepatol (2008) 0.88
High resolution and high definition anorectal manometry and pressure topography: diagnostic advance or a new kid on the block? Curr Gastroenterol Rep (2013) 0.86
Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep (2006) 0.86
Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf (2012) 0.85
Fecal incontinence in the elderly. Gastroenterol Clin North Am (2009) 0.85
Dietary fructose intolerance, fructan intolerance and FODMAPs. Curr Gastroenterol Rep (2014) 0.84
Anorectal motor disorders. Best Pract Res Clin Gastroenterol (2007) 0.83
Rectoanal reflexes and sensorimotor response in rectal hyposensitivity. Dis Colon Rectum (2010) 0.83
Distensibility testing of the esophagus. Ann N Y Acad Sci (2011) 0.82
Functional disorders of defecation: evaluation and treatment. Curr Treat Options Gastroenterol (2007) 0.81
Translumbar and transsacral motor-evoked potentials: a novel test for spino-anorectal neuropathy in spinal cord injury. Am J Gastroenterol (2011) 0.81
Altered esophageal sensory-motor function in patients with persistent symptoms after Nissen fundoplication. Am J Surg (2007) 0.81
Defecation disorders: neuromuscular aspects and treatment. Curr Gastroenterol Rep (2006) 0.80
Approach to fecal incontinence and constipation in older hospitalized patients. Hosp Pract (1995) (2011) 0.80
Can high-resolution anorectal manometry shed new light on defecatory disorders? Gastroenterology (2012) 0.79
Diagnostic testing in fecal incontinence. Curr Gastroenterol Rep (2003) 0.77
Lubiprostone for constipation and irritable bowel syndrome with constipation. Expert Rev Gastroenterol Hepatol (2008) 0.76
The role of rifaximin therapy in patients with irritable bowel syndrome without constipation. Expert Rev Gastroenterol Hepatol (2011) 0.76
What's in a name? Putting patients first: biofeedback for irritable bowel syndrome patients with dyssynergic defecation. J Clin Gastroenterol (2011) 0.75
The evolution of evaluation and management of urinary or fecal incontinence and pelvic organ prolapse. Curr Probl Surg (2015) 0.75
Small intestinal fungal overgrowth. Curr Gastroenterol Rep (2015) 0.75
[Current concepts in the pathophysiology, diagnosis and treatment of fecal incontinence]. Rev Gastroenterol Mex (2007) 0.75
Functional colonic and anorectal disorders. Postgrad Med (1995) 0.75
The evolution of evaluation and management of urinary or fecal incontinence and pelvic organ prolapse. Curr Probl Surg (2015) 0.75
Esophageal pressure topography, body position, and hiatal hernia. J Clin Gastroenterol (2014) 0.75
[It's necessary the anorrectal manometry for evaluation of patients with chronic constipation?]. Rev Gastroenterol Mex (2009) 0.75
Two Cases of Chronic Intestinal Pseudo-obstruction: A Comparison of Staining Characteristics of Enteric Visceral Myopathy With Hirschsprung Disease. Appl Immunohistochem Mol Morphol (2016) 0.75